Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Platform
  • Pipeline
  • Patients
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
    • Job Openings
  • Contact
  • News & Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
Jun 02, 2022 8:00am EDT

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

May 18, 2022 8:00am EDT

Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

May 11, 2022 7:00am EDT

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 04, 2022 8:00am EDT

Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

Mar 01, 2022 7:00am EST

Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

Feb 23, 2022 8:00am EST

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

Jan 14, 2022 8:00am EST

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa

Jan 03, 2022 7:00am EST

Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402

Nov 11, 2021 8:05am EST

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

Nov 08, 2021 8:00am EST

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …25
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2023 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences